Literature DB >> 7662963

The ski/sno protooncogene family in hematopoietic development.

S Pearson-White1, D Deacon, R Crittenden, G Brady, N Iscove, P J Quesenberry.   

Abstract

The ski/sno protooncogenes encode nuclear proteins that may act as transcription factors. We examined ski and sno mRNA expression in hemolymphopoietic lineages. The ski protooncogene is expressed in B- and T-lineage cells, mature macrophages, and mast cells. In normal murine marrow-derived progenitors analyzed by single-cell reverse transcription-polymerase chain reaction (RT-PCR), ski expression is limited to dual-lineage megakaryocyte/erythrocyte colony-starts. Expression of sno is more limited than ski in mature cells; it is expressed in T lymphopoietic cells, but not in B-lineage cells. The sno protooncogene is expressed more widely than ski in myeloid progenitors, as it is found consistently in tri-, dual-, and single-lineage progenitors. Both ski and sno are cell cycle-regulated in synchronized factor-dependent mouse myeloid cells. Expression of ski mRNA peaks in mid G1 in cells synchronized by isoleucine deprivation in the presence of growth factor, but falls off rapidly when growth factor is withdrawn. Expression of sno mRNA is maximal in early to mid G1 and then oscillates as the cells continue through cycle. These results suggest that the ski/sno protooncogenes play a role in hematopoiesis, growth factor responses, and cell cycle-regulation, with the two members of the family showing differing properties.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7662963

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Proto-oncogene Sno expression, alternative isoforms and immediate early serum response.

Authors:  S Pearson-White; R Crittenden
Journal:  Nucleic Acids Res       Date:  1997-07-15       Impact factor: 16.971

Review 2.  Single-cell analysis of gene expression in the nervous system. Measurements at the edge of chaos.

Authors:  D K O'Dowd; M A Smith
Journal:  Mol Neurobiol       Date:  1996-12       Impact factor: 5.590

3.  The SKI proto-oncogene enhances the in vivo repopulation of hematopoietic stem cells and causes myeloproliferative disease.

Authors:  Sofie Singbrant; Meaghan Wall; Jennifer Moody; Göran Karlsson; Alistair M Chalk; Brian Liddicoat; Megan R Russell; Carl R Walkley; Stefan Karlsson
Journal:  Haematologica       Date:  2014-01-10       Impact factor: 9.941

4.  An efficient strategy to identify early TPA-responsive genes during differentiation of HL-60 cells.

Authors:  Ling-Yueh Hu; Clifford G Tepper; Su-Hao Lo; Wen-Chang Lin
Journal:  Gene Expr       Date:  2006

Review 5.  SnoN in mammalian development, function and diseases.

Authors:  Nadine S Jahchan; Kunxin Luo
Journal:  Curr Opin Pharmacol       Date:  2010-09-06       Impact factor: 5.547

6.  Defective T-cell activation is associated with augmented transforming growth factor Beta sensitivity in mice with mutations in the Sno gene.

Authors:  S Pearson-White; M McDuffie
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

Review 7.  Ski and SnoN, potent negative regulators of TGF-beta signaling.

Authors:  Julien Deheuninck; Kunxin Luo
Journal:  Cell Res       Date:  2009-01       Impact factor: 25.617

8.  The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain.

Authors:  Kristie L Durst; Bart Lutterbach; Tanawan Kummalue; Alan D Friedman; Scott W Hiebert
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

9.  Ski negatively regulates erythroid differentiation through its interaction with GATA1.

Authors:  Nobuhide Ueki; Leiqing Zhang; Michael J Hayman
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

10.  The GATA1s isoform is normally down-regulated during terminal haematopoietic differentiation and over-expression leads to failure to repress MYB, CCND2 and SKI during erythroid differentiation of K562 cells.

Authors:  Christina Halsey; Marie Docherty; Mhairi McNeill; Derek Gilchrist; Michelle Le Brocq; Brenda Gibson; Gerard Graham
Journal:  J Hematol Oncol       Date:  2012-08-01       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.